Abstract: Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2.

Abstract: Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2.

Abstract: An audio/video (AV) receiver is adapted to be dynamically reconfigured in a selected one of an encrypted content support mode and an unencrypted content support mode. The AV receiver includes a controller configured to dynamically alter one or more encryption settings based at least in part on user input provided to a mode toggle mechanism. The one or more altered encryption settings are effective to facilitate presentation of unencrypted content within a received media stream on a display while selectively preventing presentation of encrypted content included in the received media stream on the display.

Abstract: An audio/video (AV) receiver is adapted to be dynamically reconfigured in a selected one of an encrypted content support mode and an unencrypted content support mode. The AV receiver includes a controller configured to dynamically alter one or more encryption settings based at least in part on user input provided to a mode toggle mechanism. The one or more altered encryption settings are effective to facilitate presentation of unencrypted content within a received media stream on a display while selectively preventing presentation of encrypted content included in the received media stream on the display.

Abstract: An audio/video (AV) receiver is adapted to be dynamically reconfigured in a selected one of an encrypted content support mode and an unencrypted content support mode. The AV receiver includes a controller configured to dynamically alter one or more encryption settings based at least in part on user input provided to a mode toggle mechanism. The one or more altered encryption settings are effective to facilitate presentation of unencrypted content within a received media stream on a display while selectively preventing presentation of encrypted content included in the received media stream on the display.

Abstract: Immune cell engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20 and/or overexpress one or more of exogenous TCF7 and Bach2. Method of treating cancer, comprising administering the cells described herein. Method of increasing one or more of a peak fold proliferation rate, a killing efficiency, or inducing the cellular characteristics associated with naïve phenotype of an immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and Bach2. Method of generating a modified immune cell, comprising introducing an exogenous construct encoding a CAR or a TCR, and inhibiting the endogenous expression of one or more of Blimp-1 and A20, and/or introducing an exogenous construct encoding one or more of TCF7 and B ach2.